Microbiota Transplantation Among Patients Receiving Long-Term Care
Mikrobiota-Transplantation bei Patient:innen in der Langzeitpflege
JAMA Network Open · 24.07.2025 · 8 (7) · e2522740
DOI: 10.1001/jamanetworkopen.2025.22740 ↗Auf einen Blick
In einer nicht randomisierten Pilotstudie war FMT bei LTACH-Patient:innen akzeptabel und ohne zugeordnete schwerwiegende unerwünschte Ereignisse. Effekte auf MDRO-Besiedlung, Bakteriämie und Antibiotikagebrauch waren nicht gesichert.
Fragestellung
Ist FMT bei LTACH-Patient:innen sicher und akzeptabel?
Methode
Einzentrische, offene, nicht randomisierte klinische Studie von April bis Dezember 2023 in einem LTACH im Südosten der USA; Auswertung August 2024 bis Mai 2025.
Ergebnisse
42 Patient:innen: 10 erhielten FMT, 32 dienten als Kontrollen. Keine schwerwiegenden, FMT-zugeordneten unerwünschten Ereignisse; unerwünschte Ereignisse nach FMT waren mild. Alle perirektalen Kulturen bei FMT-Empfänger:innen zeigten am Endbesuch weiter mindestens 1 MDRO.
Einschränkungen
Nicht randomisiert; nicht gepowert für die untersuchten Wirksamkeitsendpunkte.
Schlussfolgerung der Autor:innen
FMT war für LTACH-Patient:innen akzeptabel und ohne zugeordnete schwerwiegende unerwünschte Ereignisse. Größere randomisierte Studien sind laut Autor:innen erforderlich.
Kernaussagen
- Keine schwerwiegenden FMT-zugeordneten unerwünschten Ereignisse
- Alle perirektalen Kulturen bei FMT-Empfänger:innen weiter MDRO-positiv
- Mögliche Reduktionen von Bakteriämie und Antibiotikagebrauch, aber nicht signifikant
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie in der Zeitschrift JAMA Network Open, online erschienen am 24.07.2025. Verfasst von Michael H Woodworth und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Long-Term Care. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Themen: Langzeitpflege
Abstract (Originalsprache)
Importance Intestinal multidrug-resistant organism (MDRO) colonization is highly prevalent in long-term acute care hospital (LTACH) patients and is associated with MDRO infection and transmission. However, there are no therapies approved by the US Food and Drug Administration to reduce intestinal MDRO colonization.
Objective
To determine the safety and acceptability of fecal microbiota transplantation (FMT) in LTACH patients. Design, Setting, and Participants This single-center, open-label nonrandomized clinical trial was conducted from April to December 2023 at an LTACH in the Southeastern US with median 50-patient census and 28-day length of stay. Patients with MDRO colonization were identified by perirectal prevalence sampling. Patients colonized with at least 1 target MDRO were approached for informed consent for FMT. FMT recipients were compared with untreated controls with MDRO colonization. Data were analyzed from August 2024 to May 2025.
Intervention
Healthy donor fecal microbiota (50-100 g stool and 250 mL normal saline with 9% glycerol) instilled via gastrostomy tube or enema without antibiotic or bowel preparation conditioning. Main Outcomes and Measures The primary outcome was frequency and severity of adverse events. Solicited adverse events were recorded for 7 days. Unsolicited adverse events were recorded for 6 months. Four weekly perirectal MDRO cultures were performed after FMT.
Results
A total of 42 patients, including 10 (mean [SD] age, 63.8 (14.5) years; 7 [70%] female) who received FMT and 32 contemporaneous controls (mean [SD] age, 64.0 [13.7] years; 13 [41%] female) were assessed. In 2 prevalence surveys, 23 of 32 (72%) and 26 of 34 (77%) perirectal cultures grew at least 1 MDRO. Among the FMT group, 5 patients received FMT via gastrostomy alone, 4 via enema alone, and 1 with both routes more than 30 days apart. No serious adverse events were attributed to FMT, and post-FMT solicited adverse events were mild. At final visit, all perirectal cultures from FMT recipients grew at least 1 MDRO. Post hoc analyses found numerically fewer FMT recipients had positive blood culture results (0 individuals vs 6 individuals [19%]; P = .31), pathogen intestinal dominance (2 of 8 individuals [25%] vs 4 of 8 individuals [50%]; P = .61), and 7 fewer days of antibiotic therapy per 1000 patient days (median [IQR], 12.6 [0-25.2] days vs 19.7 [6.5-36.1] days; P = .38) compared with controls in the 6 months after prevalence survey, although these differences were not statistically significant. Accounting for higher baseline FMT recipient antibiotic use, difference-in-differences analysis estimated 26 (95% CI, −64 to 12) fewer days of antibiotic therapy per 1000 patient-days after FMT, although this difference was also not statistically significant. Conclusions and Relevance In this nonrandomized pilot clinical trial, FMT was acceptable for LTACH patients without related serious adverse events. Although not powered to test these outcomes, this study found potential reductions in bacteremia, intestinal pathogen domination, and antibiotic use associated with FMT, suggesting FMT should be evaluated in larger, randomized trials. Trial Registration ClinicalTrials.gov Identifier: NCT05780801
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
- Division of Hospital Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
- Emory Long Term Acute Care, Decatur, Georgia.
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
- Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City.
- Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore.
Förderung
- NIAID NIH HHS
Zitieren
APA
Woodworth, M. H., Babiker, A., Prakash-Asrani, R., Mehta, C. C., Steed, D. B., Ashley, A., Koundakjian, D., Acharya, A., Grooms, L., Bower, C. W., Suchindran, D. R., Trehan, T., Halpin, A. L., Spalding Walters, M., Reddy, S. C., Samore, M. H., Roghmann, M. C., Hayden, M. K., Van Riel, J., …, & Fridkin, S. K. (2025). Microbiota Transplantation Among Patients Receiving Long-Term Care. JAMA Network Open, 8(7), e2522740. https://doi.org/10.1001/jamanetworkopen.2025.22740
Vancouver
Woodworth MH, Babiker A, Prakash-Asrani R, Mehta CC, Steed DB, Ashley A, et al. Microbiota Transplantation Among Patients Receiving Long-Term Care. JAMA Network Open. 2025;8(7):e2522740. doi:10.1001/jamanetworkopen.2025.22740
BibTeX
@article{Woodworth2025,
author = {Woodworth, Michael H and Babiker, Ahmed and Prakash-Asrani, Radhika and Mehta, C Christina and Steed, Danielle Barrios and Ashley, Amanda and Koundakjian, Dylan and Acharya, Adi and Grooms, Lori and Bower, Chris W and Suchindran, Deepti R and Trehan, Twinkle and Halpin, Alison Laufer and Spalding Walters, Maroya and Reddy, Sujan C and Samore, Matthew H and Roghmann, Mary-Claire and Hayden, Mary K and Van Riel, Julia and Burd, Eileen M and Lohsen, Sarah and Satola, Sarah W and Fridkin, Scott K},
title = {Microbiota Transplantation Among Patients Receiving Long-Term Care},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {7},
pages = {e2522740},
doi = {10.1001/jamanetworkopen.2025.22740}
}
EUVIMED